Katherine graduated with an MChem in Chemistry from the University of Oxford in 2002, spending the fourth year as a member of the Jeremy Robertson group working on radical cyclisation reactions. Over the next 9 years she worked in Pfizer’s medicinal chemistry department in Sandwich, UK on a variety of drug discovery programmes in the allergy and respiratory, cardiovascular and genitourinary therapeutic areas.
She joined the group in 2011, working on the discovery of chemical probes for the JumonjiC domain containing histone lysine demethylases.
C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays.
Le Bihan Y-V. et al, (2019), European journal of medicinal chemistry, 177, 316 - 337
Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin
Jones P. et al, (2017), Journal of Medicinal Chemistry, 60, 767 - 786
An improved synthesis of a novel α1A partial agonist including a new two-step synthesis of 4-fluoropyrazole
England K. et al, (2010), Tetrahedron Letters, 51, 2849 - 2851